## Edgar Filing: MAULDIN JOHN F - Form 4

Form 4								
April 01, 2013 FORM 4 UNITED	STATES SECU				COMMISSION	N OMB	PPROVAL 3235-0287	
Section 16.	TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF					Number: Expires: Estimated burden hou	January 31, 2005 average	
abligations	(a) of the Public	Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					. 0.5	
(Print or Type Responses)								
		2. Issuer Name <b>and</b> Ticker or Trading Symbol GALECTIN THERAPEUTICS INC [GALT]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) () C/O GALECTIN THERAPE INC., 4960 PEACHTREE INDUSTRIAL BLVD, STE	(Month EUTICS 03/28/	of Earliest Tr /Day/Year) /2013	ansaction		X Director Officer (giv below)		% Owner her (specify	
Filed		If Amendment, Date Original led(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
NORCROSS, GA 30071					Person	wore than one R	eporting	
(City) (State)	(Zip) Ta	ble I - Non-D	erivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		Transaction Code	4. Securiti Acquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line	e for each class of se	Code V		(D) Price	(Instr. 3 and 4)			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: MAULDIN JOHN F - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 3.59	03/28/2013		А	16,714	<u>(1)</u>	03/28/2023	Common Stock	16,714	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships					
		Director	10% Owner	Officer	Other		
MAULDIN JOHN F C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD, STE 240 NORCROSS, GA 30071		Х					
Signatures							
/s/ John F. Mauldin	04/01/2013						
**Signature of	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests quarterly in eight equal installments beginning on May 12, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Person

8 E S ()